Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Welcome and Introduction to Vi3C

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Opening Session Panel Discussion

Advertisement

Advertisement




Jun
09
Today In Oncology
Daraxonrasib Nearly Doubles Survival in Previously Treated Metastatic Pancreatic Cancer
Teclistamab in Previously Treated Multiple Myeloma
Addition of Talazoparib to Enzalutamide in Metastatic Androgen Pathway Modulation–Sensitive Prostate Cancer
Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma
Sunvozertinib in NSCLC With EGFR Exon 20 Insertion Mutations
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo